Home > Newsletters > Drug Industry Daily > J&J Settles Risperdal-Related Consumer Fraud Claims With 36 States, DC for $181 Million
Drug Industry Daily
Aug. 31, 2012 | Vol. 11 No. 172
J&J Settles Risperdal-Related Consumer Fraud Claims With 36 States, DC for $181 Million
Johnson & Johnson (J&J) has agreed to pay $181 million and enter into a consent decree with 36 states and the District of Columbia to settle allegations that its Janssen subsidiary marketed prescription antipsychotic Risperdal off-label in violation of consumer protection laws, J&J says.
ePublishing :: CMS, Hosting & Web Development | © Copyright by FDAnewsAll rights reserved. Do not duplicate or redistribute in any form.